Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) and Profound Medical (NASDAQ:PROF – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.
Risk & Volatility
Reviva Pharmaceuticals has a beta of 0.06, suggesting that its stock price is 94% less volatile than the S&P 500. Comparatively, Profound Medical has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500.
Valuation & Earnings
This table compares Reviva Pharmaceuticals and Profound Medical”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Reviva Pharmaceuticals | N/A | N/A | -$29.92 million | ($0.46) | -0.64 |
| Profound Medical | $14.30 million | 19.70 | -$27.82 million | ($1.34) | -5.79 |
Profound Medical has higher revenue and earnings than Reviva Pharmaceuticals. Profound Medical is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Reviva Pharmaceuticals and Profound Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Reviva Pharmaceuticals | N/A | -20,501.80% | -187.50% |
| Profound Medical | -275.16% | -86.18% | -70.55% |
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Reviva Pharmaceuticals and Profound Medical, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Reviva Pharmaceuticals | 1 | 0 | 7 | 0 | 2.75 |
| Profound Medical | 1 | 0 | 1 | 0 | 2.00 |
Reviva Pharmaceuticals currently has a consensus target price of $3.33, indicating a potential upside of 1,039.21%. Profound Medical has a consensus target price of $12.00, indicating a potential upside of 54.64%. Given Reviva Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Reviva Pharmaceuticals is more favorable than Profound Medical.
Institutional and Insider Ownership
63.2% of Reviva Pharmaceuticals shares are held by institutional investors. Comparatively, 47.9% of Profound Medical shares are held by institutional investors. 8.9% of Reviva Pharmaceuticals shares are held by company insiders. Comparatively, 1.5% of Profound Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Reviva Pharmaceuticals beats Profound Medical on 8 of the 13 factors compared between the two stocks.
About Reviva Pharmaceuticals
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.
About Profound Medical
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.
Receive News & Ratings for Reviva Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reviva Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
